Question special

Chest pain is among the leading patient complaints in the emergency department and ambulance services. Historically, routine oxygen supplementation was recommended in all patients with symptoms suggestive of AMI, owing to its "low risk of harm" and potential benefits. In particular, ambulance services have a long history of delivering high concentration oxygen therapy to patients irrespective of peripheral oxygen saturation . The cost of providing a treatment with little clinical value is now in question.

I wonder if one of the authors could comment on the cost of providing oxygen therapy in the context of the DETO2X protocol? Indeed this trial has enormous efficiency benefits if translated into practice, so I'd be very interested to hear what the cost implications would be if we withheld routine oxygen supplementation in this large population of patients?